These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17684474)

  • 21. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of antidepressant response.
    Keers R; Aitchison KJ
    Expert Rev Neurother; 2011 Jan; 11(1):101-25. PubMed ID: 21158559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group.
    Bromley CM; Close S; Cohen N; Favis R; Fijal B; Gheyas F; Liu W; Lopez-Correa C; Prokop A; Singer JB; Snapir A; Tchelet A; Wang D; Goldstaub D;
    Pharmacogenomics J; 2009 Feb; 9(1):14-22. PubMed ID: 18794908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FPIN's clinical inquiries. Psychosocial interventions delivered by primary care physicians to patients with depression.
    Clark MS; Smith PO; Payne TJ; Lo V
    Am Fam Physician; 2006 Nov; 74(9):1580-1. PubMed ID: 17111900
    [No Abstract]   [Full Text] [Related]  

  • 25. The rater and rating instrument as sources of variance in evaluating drug efficacy in depression.
    Raskin A; Crook T
    Psychopharmacol Bull; 1975 Jul; 11(3):16-7. PubMed ID: 1153643
    [No Abstract]   [Full Text] [Related]  

  • 26. Ancillary risk information and pharmacogenetic tests: social and policy implications.
    Henrikson NB; Burke W; Veenstra DL
    Pharmacogenomics J; 2008 Apr; 8(2):85-9. PubMed ID: 17486108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetics and personalized medicine in antidepressant treatment.
    Gvozdic K; Brandl EJ; Taylor DL; Müller DJ
    Curr Pharm Des; 2012; 18(36):5853-78. PubMed ID: 22681166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Should the treatment of depression in the Netherlands be changed after the STAR*D study?].
    Paalvast Y; Nolen WA
    Tijdschr Psychiatr; 2008; 50(4):223-8. PubMed ID: 18398802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression.
    Domschke K; Dannlowski U; Ohrmann P; Lawford B; Bauer J; Kugel H; Heindel W; Young R; Morris P; Arolt V; Deckert J; Suslow T; Baune BT
    Eur Neuropsychopharmacol; 2008 Oct; 18(10):751-9. PubMed ID: 18579347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics: from bench to byte.
    Swen JJ; Wilting I; de Goede AL; Grandia L; Mulder H; Touw DJ; de Boer A; Conemans JM; Egberts TC; Klungel OH; Koopmans R; van der Weide J; Wilffert B; Guchelaar HJ; Deneer VH
    Clin Pharmacol Ther; 2008 May; 83(5):781-7. PubMed ID: 18253145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smoking cessation treatment: pharmacogenetic assessment.
    Munafò MR; Lerman C; Niaura R; Shields AE; Swan GE
    Curr Opin Mol Ther; 2005 Jun; 7(3):202-8. PubMed ID: 15977416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methodological quality of pharmacogenetic studies: issues of concern.
    Jorgensen AL; Williamson PR
    Stat Med; 2008 Dec; 27(30):6547-69. PubMed ID: 18837075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Follow-up of antidepressive therapy in psychiatric clinical practice].
    Vandel B; Perault MC
    Therapie; 1995; 50(6):511-3. PubMed ID: 8745949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials.
    Fabbri C; Zohar J; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():36-44. PubMed ID: 29777729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethical problems in pharmacogenetic studies of psychiatric disorders.
    Serretti A; Artioli P
    Pharmacogenomics J; 2006; 6(5):289-95. PubMed ID: 16550208
    [No Abstract]   [Full Text] [Related]  

  • 36. Resolving the onset of antidepressants' clinical actions: critical for clinical practice and new drug development.
    Katz MM; Bowden CL; Berman N; Frazer A
    J Clin Psychopharmacol; 2006 Dec; 26(6):549-53. PubMed ID: 17110809
    [No Abstract]   [Full Text] [Related]  

  • 37. Eighteen months of drug treatment for depression: predicting relapse and recovery.
    Mulder RT; Frampton CM; Luty SE; Joyce PR
    J Affect Disord; 2009 Apr; 114(1-3):263-70. PubMed ID: 18805590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Basic problems in clinical testing of antidepressive drugs].
    Immich H; Eckmann F; Neumann H; Schäpperle O; Schwarz H; Tempel H
    Arzneimittelforschung; 1971 May; 21(5):644-9. PubMed ID: 4936794
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacogenetics in clinical practice: considerations for testing.
    Constable S; Johnson MR; Pirmohamed M
    Expert Rev Mol Diagn; 2006 Mar; 6(2):193-205. PubMed ID: 16512779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale.
    Sheehan KH; Sheehan DV
    Int Clin Psychopharmacol; 2008 Mar; 23(2):70-83. PubMed ID: 18301121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.